July 6, 2020 / 3:15 PM / a month ago

Johnson & Johnson cuts price of TB drug bedaquiline in poorer countries

July 6 (Reuters) - Johnson & Johnson said on Monday it was slashing the price of its version of the tuberculosis drug bedaquiline to $340 from its original price of $400, for a six-month treatment, in low- and middle-income countries, to scale up its use during the COVID-19 pandemic.

J&J’s bedaquiline, marketed under the brand name Sirturo, will be available at the reduced price to more than 135 eligible countries, through United Nations-hosted Stop TB Partnership’s Global Drug Facility (GDF), created in 2001 to negotiate lower prices for treatments.

Reporting by Manojna Maddipatla in Bengaluru; Editing by Ramakrishnan M.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below